157 related articles for article (PubMed ID: 37572533)
21. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
22. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract][Full Text] [Related]
23. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.
Jin X; Yang C; Fan P; Xiao J; Zhang W; Zhan S; Liu T; Wang D; Wu H
J Biol Chem; 2017 Apr; 292(15):6269-6280. PubMed ID: 28242758
[TBL] [Abstract][Full Text] [Related]
24. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
Mei H; Wu H; Yang J; Zhou B; Wang A; Hu C; Qi S; Jiang Z; Zou F; Wang B; Liu F; Chen Y; Wang W; Liu J; Liu Q
Signal Transduct Target Ther; 2023 Jan; 8(1):18. PubMed ID: 36642705
[TBL] [Abstract][Full Text] [Related]
25. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
26. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.
Wang J; Yu X; Gong W; Liu X; Park KS; Ma A; Tsai YH; Shen Y; Onikubo T; Pi WC; Allison DF; Liu J; Chen WY; Cai L; Roeder RG; Jin J; Wang GG
Nat Cell Biol; 2022 Mar; 24(3):384-399. PubMed ID: 35210568
[TBL] [Abstract][Full Text] [Related]
27. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
[TBL] [Abstract][Full Text] [Related]
28. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
29. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
31. Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.
Wang Z; Tan M; Su W; Huang W; Zhang J; Jia F; Cao G; Liu X; Song H; Ran H; Nie G; Wang H
J Med Chem; 2023 May; 66(9):6263-6273. PubMed ID: 37092695
[TBL] [Abstract][Full Text] [Related]
32. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
33. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
34. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
35. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues.
Shi S; Du Y; Zou Y; Niu J; Cai Z; Wang X; Qiu F; Ding Y; Yang G; Wu Y; Xu Y; Zhu Q
J Med Chem; 2022 Mar; 65(6):5057-5071. PubMed ID: 35175763
[TBL] [Abstract][Full Text] [Related]
36. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation.
Consalvi S; Brancaccio A; Dall'Agnese A; Puri PL; Palacios D
Nat Commun; 2017 Jan; 8():13956. PubMed ID: 28067271
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
38. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
39. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
[TBL] [Abstract][Full Text] [Related]
40. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]